

A study of invasive fungal infections at a tertiary level hospital: prospective study

Authors:

¹Dr. Pallavi Borase (M.D. Microbiology), ²Dr. Chhaya Chande (M.D. Microbiology), ³Dr. Kavita Bhilkar (M.D. Microbiology), ⁴Dr. Jyoti Bade (M.D. Microbiology), Dr. Ameeta Joshi (M.D. Microbiology)

Department of Microbiology, Sir Grant Government Medical College, Mumbai

Corresponding Author:

Dr. Pallavi Borase

Article Received: 05-December-2024, Revised: 25-December-2024, Accepted: 15-January-2025

ABSTRACT:

Introduction: Invasive fungal infections (IFIs) represent a major cause of increased morbidity and mortality in critically ill patients.¹ IFDs are an emerging problem worldwide, are generally very difficult to cure and the associated mortality remains very high depending on the pathogen and patient population.^{3,4} Fungal species are approximately 7 percent (6, 11,000 species) and they are distributed in soil, plant debris, and other organic substrates², approximately 600 species are human pathogens.³ Invasive fungal infection prevalence rose from 2.2% (1987) to 5.1% in last 12-year period.⁴ According to recent data, 3 million people worldwide are thought to be affected by chronic severe fungal infections, whereas approximately 1.9 million patients get acute invasive fungal infections (IFI) each year. An estimated 1.6 million fatalities per year are linked to all fungal illnesses, many of which are fatal infections.⁵ Nearly 70% of all IFIs in the world are caused by invasive candidiasis (IC), followed by cryptococcosis (20%) and aspergillosis (10%).⁶ The identification of candida species is important in the diagnostic laboratory. There is a prognostic and therapeutical significance, in the identification of candida species and thus early and correct antifungal therapy can be initiated.⁷ Antifungal resistance is a serious issue in both time and space because fungi belonging to the species Candida, Aspergillus, Cryptococcus, and Pneumocystis have been exhibiting considerable rates of antifungal resistance worldwide.^{8,9} Several new antifungals have expanded prophylaxis and treatment options for invasive fungal infections. Overview of treatment options for invasive fungal infections.¹⁰

Keywords: *Invasive fungal infections, morbidity and mortality, morbidity and mortality*

INTRODUCTION:

Aims/Objectives:

AIM:

To study the prevalence and etiology of invasive fungal infections.

OBJECTIVES:

1. To study the etiological agents causing invasive fungal infections.
2. Identify the fungi up to the species level.
3. Correlate findings of direct microscopic examinations with culture.
4. To study the risk factors associated with invasive fungal diseases.
5. To study antifungal sensitivity in candida species by conventional and automated methods.

This is a prospective descriptive study of total 293 patients admitted with signs and symptoms suggestive of invasive fungal infections (IFI) and satisfying the inclusion criteria were included in the study during a study period of 18 month in the department of Microbiology of a tertiary care centre, Mumbai

Selection Criteria:

Inclusion criteria:

Clinically suspected of fungal infections on the basis of signs and symptoms and non-responsive to broad spectrum antibiotics.

Various specimens were collected aseptically in clean sterile and properly sealed containers. All the specimens were labelled properly with full patient details, date and

time of collection.

Exclusion criteria:

All the patients of cutaneous fungal infections.

Source of samples:

Specimens collected were blood, body fluids, pleural fluid, cerebrospinal fluid, bronchoalveolar lavage, urine, pus, fine needle aspiration cytology, and surgical drain fluid.

Clinical assessment:

The detailed relevant clinical history was taken of each patient with regard to name, age, sex, clinical diagnosis, H/o antibiotic therapy, H/o clinical immune status and H/o clinical interventions.

Sample processing:

Samples were processed for microscopic examination, fungal cultures and antifungal sensitivity as follows:

Microscopic examination:

The following preparation was made:

1. Potassium hydroxide mount¹¹

For all specimens besides CSF, 10% KOH preparations were made.

2. Gram Stain¹²

3. India ink preparation¹¹

This was done for demonstrating the capsule of Cryptococcus.

Culture:

The samples were inoculated aseptically on 2 sets of Sabouraud's Dextrose Agar (SDA) and incubated at 25°C and 37 °C respectively till the growth was obtained or for a minimum of 1 month.

IDENTIFICATION OF ISOLATES:

A) Identification of yeast and yeast-like fungi:

Antimicrobial Agents	Sensitive	Intermediate	Resistance
Fluconazole	>17	14-16	<13
Caspofungin	>17	15-16	<14
Voriconazole	>17	15-16	<14

B) Identification of molds¹¹:

This was done based on the following-

1) **Colony morphology¹⁶**-color, texture (granular, velvety, cottony, etc), pigment, the surface on obverse, and pigment on reverse was noted. 2) Lactophenol Cotton Blue (LPCB) Tease mount.

2) Lactophenol Cotton Blue(LPCB) Tease mount

Slide culture¹¹:

When the growth was observed, the colony morphology was noted, a smear was made, and the gram was stained. The isolate was further processed for species identification based on microscopic & colony morphology.

a) Identification of Candida -

- 1) Germ tube test¹³
- 2) Cornmeal Tween 80 agar (Dalmau plate technique)¹¹
- 3) Sugar Fermentation¹¹
- 4)Carbohydrate Assimilation Test¹³

b) Identification of Cryptococcus¹⁴

The isolates were identified as Cryptococcus based on the following.

- 1) Colony characteristics mucoid cream to buff colored colony which Changed to brown color on prolonged incubation.
- 2) Microscopic appearance of the suspected colony on Gram stain and India ink preparation.
- 3) Growth at 37°C
- Microscopic morphology showing gram-positive, round yeast cells with single narrow-based budding denoted Cryptococcus
- 4) Hydrolysis of urea.¹¹

In vitro antifungal susceptibility test by disc diffusion method:

The strains of Candida species were subjected to susceptibility testing against Fluconazole, Caspofungin, and Voriconazole by disc diffusion test as per CLSI guidelines (2018).

Interpretation:

The zone of inhibition was measured and interpreted as follows.¹⁵

RESULTS:

A total of 293 patients admitted with signs and symptoms suggestive of invasive fungal infections (IFI) and satisfying the inclusion criteria were included in the study. A total of 100 (34%) specimens from suspected cases yielded fungi out of.

293

Cases were analysed as follow:

Age-wise Distribution of cases:

A total of 121(41%) of cases were found to be in the 41-60 years age group and 28% of cases were in the 21 – 40 years age group. The age groups of less than 20 and more than 60 showed a low prevalence 19% and 12% respectively 42 patients (14.33%) belonged to paediatric age group (<12 years)

AGE	MALE	FEMALE	TOTAL
<20	34	23	56 (19.%)
21-40	45	36	82 (28.%)
41-60	78	43	121 (41%)
>61	22	12	34 (12%)
Total	179 (61.00%)	114 (39%)	293

Table 2 : Frequency of clinical manifestations in study populations.

Sr. No	Clinical finding	Total
1	Fever	219 (75%)
2	Cough	117 (40.25)
3	Headache	86 (30.03%)
4	Altered sensorium	80 (27.30%)
5	Breathlessness	65 (22.18%)
6	Convulsions	59 (20.13%)
7	Weakness	88 (30.03%)
8	Loose motion	39 (13.31%)
9	Neck stiffness	21 (7.16%)
10	Others*	89 (30.37%)

The distribution of various specimens collected from suspected invasive fungal infections.

Blood	81
Bal	59
CSF	52
Tissue	31
Pus	24
Urine	20
TRS	20
Pleural fluid	06
Total	293

Microscopic examination showed presence of fungal elements in 94 samples including blood, BAL, Tissue, pus, Urine. Two CSF specimens showed presence of capsulated, budding yeast cells morphologically resembling *Cryptococcus*.

One specimen of BAL and pleural fluid showed the presence of fungal elements (septate hyphae with acute angle branching) Two specimen of CSF showed capsulated yeast cells of *Cr. neoformans* in india ink preparation. Culture confirmation was seen in 100 samples. The most prevalent isolates were those of *Candida*, followed by *Aspergillus* species and *Cryptococcus neoformans*.

Predisposing factors of invasive fungal infections:

Predisposing factors	No. of isolates
Prolonged stay in intensive care (>7 days)	45 (15.62)
Drug intake(corticosteroids antibiotics)	39 (13.54)
Surgical intervention	36 (12.5)
Sepsis	36 (12.5%)
HIV positive	31 (10.41%)
Diabetes mellitus	25 (8.33%)
Tuberculosis	21 (7.29%)
On catheters	18 (6.25%)
COPD	16 (5.20%)
Malignancy	13 (4.16%)
LBW with prematurity	13 (4.16%)

Predisposing factors for invasive Aspergillosis were prolonged intake of corticosteroids, HIV positive, HIV positive with tuberculosis One patient with invasive aspergillosis had chest x ray findings of old pulmonary tuberculosis with aspergillosis.

Frequency of isolation of various Candida species

Sr. No	Candida Species	Total number(%)
1	<i>C.albicans</i>	32 (34.04%)
2	<i>C.tropicalis</i>	29 (30.85%)
3	<i>C.parapsilosis</i>	23 (24.46%)
4	<i>C.guilliermondii</i>	02 (2.12%)
5	<i>C.auris</i>	06 (6.38%)
6	<i>C.duboshimulonii</i>	02 (2.12%)
Total		94

1. Antifungal Susceptibility pattern in Invasive Candidiasis:

Out of the 94 candida species, 68 species were tested for antifungal susceptibility by conventional Kirby Bauer disc diffusion method, whereas 26 were tested by VITEK 2 Compact.

In vitro susceptibilities of the candida species to the antifungal agents studied by conventional Kirby Bauer Disc Diffusion

Table 9: *C. albicans* n=27

Antifungals	S	I/SDD	R
Fluconazole	26 (96.29%)	01 (3.70%)	00 (00%)
Voriconazole	24 (88.88%)	02 (7.40%)	01 (3.70%)
Caspofungin	23 (85.18%)	01 (3.70%)	03 (11.11%)

Table 10: *C. tropicalis* n=23

Antifungals	S	I/SDD	R
Fluconazole	17 (73.91%)	01 (4.34%)	05 (21.73%)
Voriconazole	16 (69.56%)	02 (8.69%)	05 (21.73%)
Caspofungin	21 (91.30%)	01 (4.34%)	01 (4.34%)

Table 11: *C. parapsilosis* n=16

Antifungals	S	I/SDD	R
Fluconazole	11 (68.75%)	02 (11.76%)	03 (17.64%)
Voriconazole	10 (62.50%)	03 (17.64%)	03 (17.64%)
Caspofungin	13 (81.25%)	02 (11.76%)	01 (05.88%)

- Two isolates of *C. guilliermondii* showed 100% sensitivity to Fluconazole, Voriconazole and Caspofungin
- One isolate of *C. auris* showed resistance to Fluconazole and Caspofungin

Identifications and antifungals susceptibility by VITEK2 Compact automated system

Table 12: *C. albicans* n= 05

Antifungals	S	I/SDD	R
Fluconazole	05 (100%)	00 (00%)	00 (00%)
Voriconazole	04 (80.00%)	00 (00%)	01 (20.00%)
Capsfungin	04 (80%)	00 (00%)	01 (20.00%)
Micafungin	04 (80%)	00 (00%)	01 (20.00%)
Amhotericin B	04 (80%)	00 (00%)	01 (20.00%)
Flucytosin	04 (80%)	00 (00%)	01 (20.00%)

Table 13: *C. tropicalis* n=06

Antifungals	S	I/SDD	R
Fluconazole	05 (83.33%)	01 (16.66%)	00 (00%)
Voriconazole	05 (83.33%)	00 (00%)	01 (16.66%)
Capsfungin	06 (100%)	00 (00%)	00 (00%)
Micafungin	06 (100%)	00 (00%)	00 (00%)
Amhotericin B	06 (100%)	00 (00%)	00 (00%)

Flucytosin	06 (100%)	00 (00%)	00 (00%)
------------	-----------	----------	----------

Table 14: *C.parapsilosis* =07

Antifungals	S	I/SDD	R
Fluconazole	05 (71.42%)	01 (14.28%)	01 (14.28%)
Voriconazole	06 (85.71%)	00 (00%)	01 (14.28%)
Caspofungin	07 (100%)	00 (00%)	00 (00%)
Micafungin	07 (100%)	00 (00%)	00 (00%)
Amphotericin B	06 (85.71%)	00 (00%)	01 (14.28%)
Flucytosin	07 (100%)	00 (00%)	00 (00%)

One isolate of *C. guilliermondii* was sensitive to Fluconazole, Voriconazole, Caspofungin, Micafungin, Amphotericin B and Flucytosin.

Table 15: *C. auris* n=05

Antifungals	S	I/SDD	R
Fluconazole	02 (40%)	00 (00%)	03 (60%)
Voriconazole	02 (40%)	01 (20%)	02 (40%)
Caspofungin	04 (80%)	00 (00%)	01 (20%)
Micafungin	04 (80%)	00 (00%)	01 (20%)
Amphotericin B	02 (40%)	00 (00%)	03 (60%)
Flucytosin	02 (40%)	00 (00%)	03 (60%)

Two isolates of *C. duboshimulonii* were resistant to Fluconazole, Amphotericin B and Flucytocin. One isolate of *C. duboshimulonii* was sensitive to Voriconazole, Caspofungin and Micafungin.

DISCUSSION:

The increase in immunocompromised patients suffering from various diseases has led to an increase in the global burden of invasive fungal infections (IFIs).¹⁷

The present study was carried out in the department of microbiology attached to a tertiary care hospital. During this study, all the patients admitted with signs and symptoms suggestive of invasive fungal infections (IFI) and satisfying the inclusion criteria were screened and the respective samples were taken for the confirmation of diagnosis.

In the present study majority of the patients were in the age group of 41-60 with a male predominance and a male-to-female ratio of 1.54:1. YubhishaDabas et al reported a male predominance (66%)¹⁸; Nicole Harrison et al also reported a male predominance (53.7%).¹⁹

The male predominance could be due to an increased chance of exposure to them compared to females. The aging population is especially susceptible to fungal infection due to underlying medical conditions and an increase in the rates of hospitalization.

In the present study majority of the patients were in the age group of 41-60. Yaling Li et al reported the majority of patients were above the age of 65 years (40%).²⁰

In the present study, common predisposing factors were prolonged stay in intensive care (>7 days) (15.62%) followed by prolonged exposure to corticosteroids, antibiotics(13.54%), surgical intervention(12.5%), sepsis(12.5%), AIDS(10.41%), Diabetes mellitus(8.33%), Tuberculosis(7.29%), COPD(5.20%), malignancy(4.16%), LBW with prematurity(4.16%)

Yaling Li et al reported the most common Predisposing factor prolonged hospitalization (96.1%), total parenteral nutrition (79.4%), and the presence of intravenous catheters (78.8%)²¹

In the present study, among the 100 fungal isolates, majority of them were *Candida non-albicans* (62%) followed by *Candida albicans* (32%), *Aspergillus species* (4%), and *cryptococcus neoformans* (2%).

Chakrabarti et al showed invasive candidiasis as the most common mycotic infection across India.²²

Kauffman et al also showed that the most common IFI were invasive candidiasis followed by Aspergillosis.²³

In this study, the most common Candida species isolates in blood samples were *Candida albicans* (31.37%) followed by *Candida tropicalis* (27.45%), *Candida parapsilosis* (25.49%), *Candida auris* (7.84%), *Candida duboshimulonii* (3.92%), *Candida guilliermondii* (3.92%).

Peter G. Pappas et al reported *C. albicans* (46%), *C. glabrata* (20%), *C. parapsilosis* (14%), *C. tropicalis* (12%), *C. guilliermondii* (3%) *C. krusei* (2%) in blood samples.²⁴

In this study the most common Candida species isolates in BAL were *Candida albicans* (31.25%) followed by *Candida tropicalis* (37.5%), *Candida parapsilosis* (31.25%),

Sahar Kianipour et al reported *C. albicans/dubliniensis* complex (58.6%) and nonalbicans isolates (41.4%) as common isolates in BAL.²⁵

In this study the most common Candida species isolates in urine samples were *Candida albicans* (50%), *Candida tropicalis* (25%) and *Candida parapsilosis* (25%).

Umamaheshwari S et al reported, *C. tropicalis* (46.2%), followed by *C. albicans* (19.58%), *C. glabrata* (16.06%), and *C. parapsilosis* (4.62%) in urine samples.²⁶

In the present study, the most common candida species in the pediatric population were *Candida albicans* (33.33%), *Candida tropicalis* (33.33%), and *Candida parapsilosis* (33.33%),

In the present study, *Candida albicans* showed 96.29% sensitivity to Fluconazole, 88.88% sensitivity to Voriconazole, and 85.18% sensitivity to Caspofungin by disc diffusion. *C. tropicalis* showed 73.91% sensitivity to Fluconazole, 69.56% sensitivity to Voriconazole, and 91.30% sensitivity to Caspofungin. Whereas *C. parapsilosis* showed 68.75% to Fluconazole, 62.50% sensitivity to Voriconazole and 81.25% sensitivity to Caspofungin.

Maria Noni et al reported²⁷ Among *C. albicans* isolates, fluconazole and voriconazole resistance was not detected. Regarding caspofungin, 97.7% of isolates were found to be susceptible, *Candida parapsilosis* showed 98.1% sensitivity to Caspofungin, 92.2% sensitivity to Fluconazole and 98.1% sensitivity to Voriconazole from tertiary Greek pediatric hospital.

Ajitha Reddy Edula et al reported *C. albicans* had (97.91%) sensitivity to voriconazole, (95.83%) to fluconazole, *C. tropicalis* showed (94.11%) sensitivity to voriconazole, (82.35%) to fluconazole, *C. parapsilosis* had (87.5%) sensitivity to voriconazole, (75%) to fluconazole, *C. dubliniensis* had (100%) sensitivity to voriconazole, (100%) to fluconazole.²⁸

In the present study, among the 100 fungal isolates, 4 (4%) were of *Aspergillus* species, 3 species of *Aspergillus* were grown from BAL and 1 from pleural

fluid.

Out of 3 species from BAL, two were of *Aspergillus flavus* and one was of *Aspergillus glaucus*.

One isolate of pleural fluid was of *Aspergillus flavus*.

Brandon J Webb et al reported 8.9% of *Aspergillus* species.²⁹

In our study among 100 fungal isolates 2 (2%) were of *Cryptococcus neoformans* from CSF samples.

Yaling Li et al reported *Cryptococcus neoformans* (2.8%) from CSF sample.

In our study, there was a predominance of candida species isolation, followed by *Aspergillus* species and *Cryptococcus neoformans*.

Although histoplasmosis is the most common opportunistic infection in endemic areas the disease is not frequently reported from India except for the north-eastern Indian states like West Bengal which is considered as endemic region for histoplasmosis.³¹

In the present study no evidence of histoplasmosis reported.

SUMMARY AND CONCLUSIONS:

The study was conducted in the Department of Microbiology of a Government medical college attached to a tertiary care hospital with the aim to study the prevalence and etiology of invasive fungal infections in patients with signs and symptoms suggestive of invasive fungal infections.

A total of 293 patients presenting with signs and symptoms suggestive of invasive fungal infections were studied.

Various specimens were collected aseptically including blood, body fluids, pleural fluids, cerebrospinal fluid, Bronchoalveolar lavage, urine, pus, fine needle aspiration cytology and surgical drain fluid.

The specimens were subjected to microscopic examination by KOH, Gram, and India Ink preparations.

The samples were inoculated on Sabouraud's Dextrose Agar.

The yeast identification was made by colony morphology, microscopic morphology of the growth, germ tube test, Dalmau technique on cornmeal agar, Assimilation and fermentation tests, and hydrolysis of urea.

Molds were identified by Macroscopic and microscopic morphology of growth.

In vitro antifungal susceptibility was performed against Fluconazole, Voriconazole and Caspofungin by disc diffusion method according to CLSI guidelines (2018).

There was a predominance of male patients (61%), with male to female ratio of 1.57:1. Fever was the commonest (75%) symptom followed by cough (40.25%).

The overall prevalence of invasive fungal infections was 34.12% with candidiasis as the commonest (32.08%) followed by aspergillosis (1.36%) and cryptococcosis

(0.68%).

Candidemia (Candida bloodstream infections) was the commonest (54.25%) form of infection, mainly caused by *C. albicans*.

The non albicans species isolated were *C. tropicalis*, *C. parapsilosis*, *C. auris*, *C. guilliermondii*, and *C. duobushaemulonii*.

The prevalence of cryptococcosis observed was (0.68%). No case of *Histoplasma capsulatum* was observed. In vitro antifungal susceptibility was performed by the Disc diffusion method according to CLSI guidelines (2018) and VITEK 2 Compact automated system.

REFERENCES:

1. Ferraro JP, Rea S, Kaufusi S, Goodman BE, Spalding J. Epidemiology and clinical features of invasive fungal infection in a US health care network. In Open forum infectious diseases 2018 Aug (Vol. 5, No. 8, p. ofy187). US: Oxford University Press.

2. Firacative C. Invasive fungal disease in humans: are we aware of the real impact?. Memórias do Instituto Oswaldo Cruz. 2020 Oct 9;115.

3. Opportunistic invasive fungal infections: diagnosis & clinical management Parisa Badiie and Zahra Hashemizadeh Indian J Med Res. 2014 Feb;39(2): 195–204.

4. Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond *Candida albicans* and *Aspergillus fumigatus*. J Clin Microbiol 2004;42:4419-31

5. Groll AH¹, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect, 1996, Vol 33(23-32)

6. Bongomin F, Gago S, Oladele RO, Denning DW. Global and multi-national prevalence of fungal diseases-estimate precision. J Fungi (Basel).

2017;3(4):57. <https://doi.org/10.3390/jof3040057>.

7. Melanie W. Pound Mary L. Townsend Vincent Dimondi

Dustin Wilson Richard H. Drew Medical Mycology, Volume 49, Issue 6, 1 August 2011, Pages 561–580,

8. Godoy, P.; Almeida, L.P.; Colombo, A.L. (2001). Identificación de *Candida albicans* utilizando el medio cromogénico Albicans ID.

Rev Iberoam Micol 18:197-9.

9. Arastehfar A, Gabaldón T, Garcia-Rubio R, Jenks JD, Hoenigl M, Salzer HJF, Ilkit M, Lass-Flörl C, Perlin DS. Drug-resistant fungi: an emerging challenge threatening our limited antifungal armamentarium. Antibiotics (Basel). 2020;9(12):877.

10. Menzin J, Meyers JL, Friedman M, Perfect JR, Langston AA, Danna RP, Papadopoulos G. Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients. Am J Health Syst Pharm. 2009 Oct 1;66(19):1711-7. doi: 10.2146/ajhp080325. PMID: 19767376.

11. Chakrabarti A, Shivprakash MR. Medical Mycology laboratory procedures. Post-graduate institute of Medical Education and Research, Chandigarh, India 7-233

12. Baumgartner C, Freydiere A, Gille Y. Direct identification and recognition of yeast species from clinical material by using Albicans ID and CHROMagar Candida plates. J Clin Microbiol. 1996;34:454–6.

13. Baumgartner C, Freydiere A, Gille Y. Direct identification and recognition of yeast species from clinical material by using Albicans ID and

- CHROMagar Candida plates. *J Clin Microbiol.* 1996;34:454–6.
14. Chander J. A text-book of medical mycology. 4th edition 401-433
15. White PL, Perry MD, Barnes RA. An update on the molecular diagnosis of invasive fungal disease. *FEMS Microbiol Lett.* 2009;296(1):1–10.
16. Satpute MG, Telang NV, Litake GM, Niphadkar KB, Joshi SG. Prevalence of cryptococcal meningitis at a tertiary care centre in Western India (1996–2005). *Journal of medical microbiology.* 2006 Sep;55(9):1301-2.
17. **Chongtrakool, P., S. C. Chaiyaroj, V. Vithayasai, S. Trewatcharegon, R. Teanpaisan, S. Kalnawakul, and S. Sirisinha.** 1997. Immunoreactivity of a 38-kilodalton *Penicillium marneffei* antigen with human immunodeficiency virus-positive sera. *J. Clin. Microbiol.* 35:2220-2223.
18. Fang, W., Wu, J., Cheng, M. *et al.* Diagnosis of invasive fungal infections: challenges and recent developments. *J Biomed Sci* 30, 42 (2023). <https://doi.org/10.1186/s12929-023-00926-2>
19. Dabas Y, Xess I, Pandey M, Ahmed J, Sachdev J, Iram A, Singh G, Mahapatra M, Seth R, Bakhshi S, Kumar R. Epidemiology and antifungal susceptibility patterns of invasive fungal infections (IFIs) in India: a prospective observational study. *Journal of Fungi.* 2021 Dec 30;8(1):33.
20. Harrison N, Mitterbauer M, Tobudic S, Kalhs P, Rabitsch W, Greinix H, Burgmann H, Willinger B, Presterl E, Forstner C. Incidence and characteristics of invasive fungal diseases in allogeneic hematopoietic stem cell transplant recipients: a retrospective cohort study. *BMC infectious diseases.* 2015 Dec;15(1):1-9.
21. Zhang H, Zhu A. Emerging invasive fungal infections: Clinical features and controversies in diagnosis and treatment processes. *Infection and Drug Resistance.* 2020 Feb 20:607-15.
22. Dabas Y, Xess I, Pandey M, Ahmed J, Sachdev J, Iram A, Singh G, Mahapatra M, Seth R, Bakhshi S, Kumar R. Epidemiology and antifungal susceptibility patterns of invasive fungal infections (IFIs) in India: a prospective observational study. *Journal of Fungi.* 2021 Dec 30;8(1):33.
23. Chakrabarti et al IntensiveCareMed DOI10.1007/s00134-014-3603-2 Incidence, characteristics and outcome of ICU-acquired candidemia in India Arunaloke Chakrabarti Prashant Sood Shivaprakash M. Rudramurthy Sharon Chen Harsimran Kaur Malini
24. Noni M, Stathi A, Vaki I, Velegaki A, Zachariadou L, Michos A. Changing Epidemiology of Invasive Candidiasis in Children during a 10-Year Period. *Journal of Fungi.* 2019; 5(1):19. <https://doi.org/10.3390/jof5010019>
25. appas PG, Rex JH, Lee J, Hamill RJ, Larsen RA, Powderly W, Kauffman CA, Hyslop N, Mangino JE, Chapman S, Horowitz HW, Edwards JE, Dismukes WE; NIAID Mycoses Study Group. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. *Clin Infect Dis.* 2003 Sep 1;37(5):634-43. doi: 10.1086/376906. Epub 2003 Aug 14. PMID: 12942393.
26. Balaraman L, Saritha N, Raveendran G,

Characterization of non albicans candida species and the antifungal susceptibility profile of clinical isolates. *Indian J Microbiol Res* 2018;5(3):295-298

27.Sumana MN. Retrospective analysis on distribution and antifungal susceptibility profile of *Candida* in clinical samples: a study from Southern India. *Frontiers in Public Health*. 2023 May 12;11:1160841.

28.Jantarabenjakul W, Yodkitudomying C, Chindamporn A, Suchartlikitwong P, Anugulruengkitt S, Pancharoen C, Puthanakit T. Pediatric and neonatal invasive candidiasis: Species distribution and mortality rate in a Thai tertiary care hospital. *The Pediatric Infectious Disease Journal*. 2021 Feb 1;40(2):96-102.

29.Aijaz N, Kaur K. Speciation and antifungal susceptibility pattern of *Candida* isolated from blood and body fluids. *Indian J Microbiol Res* 2023;10(1):18-21

30.Mohandas V, Ballal M. Distribution of *Candida* species in different clinical samples and their virulence: biofilm formation, proteinase and phospholipase production: a study on hospitalized patients in southern India. *Journal of global infectious diseases*. 2011 Jan;3(1):4.

31.Sanyal M. Thanmany A. Skin Sensitivity to *Histoplasma* in Calcutta and its neighbourhood. *Indian J Dermatol Veneral Leprol* 1980;46:94-8